Culture of Melanoma Cells in 3-Dimensional Architectures Results in Impaired Immunorecognition by Cytotoxic T Lymphocytes Specific for Melan-A/MART-1 Tumor-Associated Antigen
暂无分享,去创建一个
Michael Heberer | Rachel Rosenthal | Ivan Martin | R. Rosenthal | Sourabh Ghosh | D. Oertli | M. Heberer | W. Weber | Sourabh Ghosh | Anca Reschner | G. Spagnoli | Paul Zajac | Walter P. Weber | Daniel Oertli | Giulio C. Spagnoli | A. Reschner | I. Martin | P. Zajac
[1] F. Marincola,et al. Correspondence 1: Cancer vaccines: pessimism in check , 2004, Nature Network Boston.
[2] B. Brors,et al. Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-specific Genes Colocalized in Chromosomal Clusters , 2004, The Journal of experimental medicine.
[3] Pierre Validire,et al. Impact of human bladder cancer cell architecture on autologous T‐lymphocyte activation , 2002, International journal of cancer.
[4] B. Seliger,et al. HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.
[5] J. Folkman,et al. Role of cell shape in growth control , 1978, Nature.
[6] P. Robbins,et al. A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.
[7] Ivan Martin,et al. Three‐dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study , 2005, Journal of cellular physiology.
[8] G. Parmiani,et al. Vaccination of patients with solid tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Rolf M. Zinkernagel,et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.
[10] A. Anichini,et al. The paradox of T cell–mediated antitumor immunity in spite of poor clinical outcome in human melanoma , 2004, Cancer Immunology, Immunotherapy.
[11] G Vallancien,et al. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns , 2002, British Journal of Cancer.
[12] M. Mihm,et al. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[13] E. Padovan,et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. , 2003, Human gene therapy.
[14] V. Cerundolo,et al. An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions , 1999, The Journal of experimental medicine.
[15] S. Richon,et al. A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation. , 2003, Cancer research.
[16] I. S. Dunn,et al. A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter , 2001, The Journal of Immunology.
[17] I. S. Dunn,et al. Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. , 2003, Molecular cancer research : MCR.
[18] P. Meltzer,et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. , 2002, Critical reviews in oncology/hematology.
[19] R. Hamid,et al. Comparison of alamar blue and MTT assays for high through-put screening. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.
[20] E. Padovan,et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. , 2002, Human gene therapy.
[21] F. Marincola,et al. Natural T cell immunity against cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] S. Pervaiz,et al. Melanoma antigen recognition by tumour‐infiltrating T lymphocytes (TIL): effect of differential expression of Melan‐A/MART‐1 , 2000, Clinical and experimental immunology.
[23] G. Bazzoni. The JAM family of junctional adhesion molecules. , 2003, Current opinion in cell biology.
[24] U. Certa,et al. High density oligonucleotide array analysis of interferon-α2a sensitivity and transcriptional response in melanoma cells , 2001, British Journal of Cancer.
[25] F. Jotereau,et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.